Literature DB >> 33785296

The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.

Laura A Evans1, Ronald Go2, Rahma Warsame2, Bharat Nandakumar2, Francis K Buadi2, Angela Dispenzieri2, David Dingli2, Martha Q Lacy2, Suzanne R Hayman2, Prashant Kapoor2, Nelson Leung3, Amie Fonder2, Miriam Hobbs2, Yi Lisa Hwa2, Eli Muchtar2, Taxiarchis V Kourelis2, Stephen Russell2, John A Lust2, Yi Lin2, Mustaqeem Siddiqui2, Robert A Kyle2, Morie A Gertz2, S Vincent Rajkumar2, Shaji Kumar2, Wilson I Gonsalves4.   

Abstract

BACKGROUND: Multiple myeloma (MM) is a heterogeneous clonal plasma cell disorder leading to differences in clinical outcomes such as overall survival (OS) among patients. We hypothesized that with expensive, novel therapeutic agents and paradigm shifts to maintain continuous therapy and improvement in OS, patients with MM are subject to the pressures of financial toxicity and the need for social support, which may be of prognostic importance.
MATERIALS AND METHODS: In this study, we examined the records of 122,458 patients from the National Cancer Database (NCDB) to determine the significance of socioeconomic factors such as estimated annual household income and education level, which were based on the patient's ZIP Code and the United States Census Bureau's 5-year report from 2008 to 2012. These socioeconomic factors, in addition to marital status, were then assessed individually and as a cumulative socioeconomic score for prognostic significance in a cohort of 2543 patients treated at a tertiary care center utilizing known biologic risk factors, such as cytogenetic risk, International Staging System classification, and serum lactate dehydrogenase levels.
RESULTS: Only marital status and estimated annual household income at diagnosis negatively impacted OS in a univariate analysis, but not in the context of a multivariable analysis incorporating known biologic risk factors.
CONCLUSION: Future analyses in other academic and non-academic centers located in urban and rural regions are required to understand the socioeconomic drivers of OS disparity among patients with MM observed nationally.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Myeloma; Outcomes; Prognosis; Socioeconomic status; Survival

Mesh:

Year:  2021        PMID: 33785296      PMCID: PMC8592381          DOI: 10.1016/j.clml.2021.02.001

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  20 in total

Review 1.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

Review 2.  National Cancer Database: The Past, Present, and Future of the Cancer Registry and Its Efforts to Improve the Quality of Cancer Care.

Authors:  Ryan M McCabe
Journal:  Semin Radiat Oncol       Date:  2019-10       Impact factor: 5.934

3.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

4.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

5.  Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study.

Authors:  Nima Kokabi; Minzhi Xing; Richard Duszak; Richard Duszak; David H Howard; Kimberly E Applegate; Juan C Camacho; Hyun S Kim
Journal:  Future Oncol       Date:  2015-12-14       Impact factor: 3.404

Review 6.  The high price of anticancer drugs: origins, implications, barriers, solutions.

Authors:  Vinay Prasad; Kevin De Jesús; Sham Mailankody
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

7.  Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment.

Authors:  Garbriel Afram; Charlotte Gran; Johanna Borg Bruchfeld; Arnika Kathleen Wagner; Alamdar Hussain; Evren Alici; Hareth Nahi
Journal:  Eur J Haematol       Date:  2020-05-29       Impact factor: 2.997

8.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

Review 9.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

10.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

View more
  2 in total

1.  Age- and sex-matched controls should not be the standard for the Ross procedure.

Authors:  Lin Chen; Miza Salim Hammoud; Michael Jiang; Nadia H Bakir; Tara Karamlou
Journal:  JTCVS Open       Date:  2022-06-02

2.  Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations.

Authors:  Jiaxuan Xu; Peipei Xu; Qiaoyan Han; Jingjing Sun; Bing Chen; Xiaoqing Dong
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.